SLC7A14: A Potential Drug Target and Biomarker for the Treatment of Atherosclerosis

Target Name: SLC7A14

NCBI ID: G57709

SLC7A14

Other Name(s): Probable cationic amino acid transporter | PPP1R142 | S7A14_HUMAN | solute carrier family 7 (cationic amino acid transporter, y+ system), member 14 | protein phosphatase 1, regulatory subunit 142 | solute carrier family 7 member 14 | solute carrier family 7 (orphan transporter), member 14 | Solute carrier family 7 member 14 | KIAA1613 | Solute carrier family 7 (cationic amino acid transporter, y+ system), member 14

SLC7A14: A Potential Drug Target and Biomarker for the Treatment of Atherosclerosis

Atherosclerosis is a leading cause of cardiovascular disease, accounting for approximately 70% of all cardiovascular deaths worldwide. It is characterized by the buildup of plaque in the arterial walls, which can lead to narrowing or blockages of the blood flow. The most common type of atherosclerosis is the buildup of plaque in the carotid arteries, which can cause sudden and severe blockages, leading to heart attacks and strokes.

Several treatment options are currently available for patients with atherosclerosis, including medications that aim to dissolve the plaque or prevent its formation. However, these treatments can have significant side effects and may not be effective in all cases. As a result, there is a need for new and more effective treatments that can specifically target the underlying cause of atherosclerosis.

SLC7A14: A Potential Drug Target

SLC7A14 is a protein that is expressed in the endothelial cells of the body. It is a cationic amino acid transporter, which means it helps to transport positively charged amino acids across cell membranes. SLC7A14 has been shown to be expressed in the endothelial cells of the brain, heart, and kidneys, which are all areas where plaque buildup is known to occur.

Recent studies have suggested that SLC7A14 may be a drug target that can be targeted with small molecules. By blocking the function of SLC7A14, researchers have found that they can prevent the formation of plaque in the endothelial cells, which may lead to the regression of existing plaque.

SLC7A14 has also been shown to be involved in the regulation of cellular signaling pathways that are important for the development of plaque. For example, studies have shown that SLC7A14 is involved in the regulation of the angiogenesis factor, which is a protein that promotes the growth and development of new blood vessels.

In addition, SLC7A14 has been shown to play a role in the regulation of the immune response. Studies have shown that SLC7A14 is involved in the regulation of the production of immune cells that are important for fighting off plaque.

SLC7A14 as a Biomarker

The buildup of plaque in the arterial walls can be detected using several biomarkers, including C-reactive protein (CRP), plasma ether extract (PE), and BNP. However, these biomarkers may not be specific to atherosclerosis, as they can be elevated in other conditions.

SLC7A14 has been shown to be a potential biomarker for atherosclerosis because it is expressed in the endothelial cells, which are the cells that line the arterial walls. This means that the buildup of SLC7A14 in these cells may be an indicator of the presence of plaque.

Studies have shown that the expression of SLC7A14 is significantly increased in endothelial cells that have been exposed to SLC7A14 inhibitors. This suggests that SLC7A14 may be a useful biomarker for the detection and treatment of atherosclerosis.

Conclusion

In conclusion, SLC7A14 is a protein that has been shown to be involved in the regulation of several cellular processes that are important for the development and progression of atherosclerosis. Its expression in endothelial cells makes it a potential biomarker for the detection and treatment of this condition. Further research is needed to fully understand the role of SLC7A14 in atherosclerosis and to develop effective treatments that target this protein.

Protein Name: Solute Carrier Family 7 Member 14

Functions: May be involved in arginine transport

The "SLC7A14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC7A14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets